Here is what the page “CAR T Cells Engineered with Extra Receptor Stay in Bone Marrow to Fight Cancer in Mice” contains. CAR T-cell therapy has revolutionized treatment for certain blood cancers by reprogramming a patient's immune cells to attack tumors. However, extending this success to solid tumors and bone metastases has been challenging. Now, scientists at the University of Pennsylvania have engineered CAR T cells to express an additional receptor that helps them home to and persist in the bone marrow, a common site for cancer spread.
In mouse models of multiple myeloma and breast cancer bone metastasis, the modified cells showed enhanced bone marrow retention and improved tumor control compared to standard CAR T cells. This approach could address a major hurdle in treating bone-homing cancers. The study, published in Science Translational Medicine, highlights the potential of targeting the bone marrow niche to improve CAR T efficacy. The full version stays on the original page, which this listing opens directly.